<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-title>BMC Infectious Diseases</journal-title><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15679899</article-id><article-id pub-id-type="pmc">PMC548682</article-id><article-id pub-id-type="publisher-id">1471-2334-5-5</article-id><article-id pub-id-type="doi">10.1186/1471-2334-5-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Daily antibiotic cost of nosocomial infections in a Turkish university hospital</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Inan</surname><given-names>Dilara</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>inan@akdeniz.edu.tr</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Saba</surname><given-names>Rabin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>rabin@akdeniz.edu.tr</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Gunseren</surname><given-names>Filiz</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>filizg@akdeniz.edu.tr</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Ongut</surname><given-names>Gozde</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>gozdeongut@yahoo.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Turhan</surname><given-names>Ozge</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ozgeturhan@akdeniz.edu.tr</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Yalcin</surname><given-names>Ata Nevzat</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>anyalcin@yahoo.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Mamikoglu</surname><given-names>Latife</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lmamikoglu@yahoo.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Akdeniz University, Antalya, Turkey</aff><aff id="I2"><label>2</label>Department of Medical Microbiology, Faculty of Medicine, Akdeniz University, Antalya, Turkey</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>31</day><month>1</month><year>2005</year></pub-date><volume>5</volume><fpage>5</fpage><lpage>5</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/5/5"/><history><date date-type="received"><day>18</day><month>6</month><year>2004</year></date><date date-type="accepted"><day>31</day><month>1</month><year>2005</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2005 Inan et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Inan et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Inan
               Dilara
               
               inan@akdeniz.edu.tr
            </dc:author><dc:title>
            Daily antibiotic cost of nosocomial infections in a Turkish university hospital
         </dc:title><dc:date>2005</dc:date><dcterms:bibliographicCitation>BMC Infectious Diseases 5(1): 5-. (2005)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2334(2005)5:1&#x0003c;5&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2334</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Many studies associated nosocomial infections with increased hospital costs due to extra days in hospital, staff time, extra investigations and drug treatment. The cost of antibiotic treatment for these infections represents a significant part of hospital expenditure. This prospective observational study was designed to determine the daily antibiotic cost of nosocomial infections per infected adult patient in Akdeniz University Hospital.</p></sec><sec sec-type="methods"><title>Methods</title><p>All adult patients admitted to the ICUs between January 1, 2000, and June 30, 2003 who had only one nosocomial infection during their stay were included in the study. Infection sites and pathogens, antimicrobial treatment of patient and it's cost were recorded. Daily antibiotic costs were calculated per infected patient.</p></sec><sec><title>Results</title><p>Among the 8460 study patients, 817 (16.6%) developed 1407 episodes of nosocomial infection. Two hundred thirty three (2.7%) presented with only one nosocomial infection. Mean daily antibiotic cost was $89.64. Daily antibiotic cost was $99.02 for pneumonia, $94.32 for bloodstream infection, $94.31 for surgical site infection, $52.37 for urinary tract infection, and $162.35 for the other infections per patient. The treatment of <italic>Pseudomonas aeruginosa </italic>infections was the most expensive infection treated. Piperacillin-tazobactam and amikacin were the most prescribed antibiotics, and meropenem was the most expensive drug for treatment of the nosocomial infections in the ICU.</p></sec><sec><title>Conclusions</title><p>Daily antibiotic cost of nosocomial infections is an important part of extra costs that should be reduced providing rational antibiotic usage in hospitals.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Nosocomial infections are frequent complications of hospitalization and also an important public health problem in developing countries, as well as in developed ones. The socioeconomic impact, ie, prolongation of hospitalization, mortality, and cost of these infections adversely effects patients and nations' economic well-being [<xref ref-type="bibr" rid="B1">1</xref>]. The cost of nosocomial infections includes increased length of hospital stay, staff time, laboratory cultures of pathogens and antimicrobial treatment [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. Although, cost of antimicrobial treatment is an important part of health expenditure, data on this subject are extremely limited in Turkey.</p><p>The aim of our study was to determine daily antibiotic cost of nosocomial infection per infected patient in a university hospital.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>The hospital setting</title><p>Akdeniz University Hospital is a 600-bed tertiary referral centre in Antalya, Turkey, treating 27 000 patients per year. The study was conducted in six adult medical and surgical intensive care units (ICUs) with a total of 51 ICU beds. Neonatal ICU was not included in the study. Since 1993, the institutional policies of hospital infection control have been implemented by infection control team.</p></sec><sec><title>Definitions and study population</title><p>In our hospital, routine prospective, active surveillance of nosocomial infections in all ICUs is performed by one infection control nurse, supervised by an infection control physician. Nosocomial infections are defined using the Centers for Disease Control and Prevention criteria [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. We do not follow patients for signs of infection after discharge unless they are readmitted to the hospital.</p><p>Between January 1, 2000 and June 30, 2003, all inpatients hospitalized in one of the adult ICUs were included in this study. Data on antimicrobial treatment were recorded for patients aged 15 or above presenting with only one nosocomial infection. For all patients included in the study, the following were recorded: age, sex, infection site, microbiologic data, antimicrobial therapy and antibiotic cost.</p></sec><sec><title>Measurement of costs</title><p>In our ICUs, all antimicrobial prescriptions are recommended by an infectious disease consultant. Antimicrobial agents prescribed only for therapeutic indications were recorded. The daily antibiotic cost was calculated in US dollars based on June 2003 prices of antimicrobial agents provided by the hospital pharmacy. The daily antibiotic cost per infected patient was calculated by the multiplication of box price and number of daily doses that was used for that infection. Two costs were calculated for each antimicrobial; the minimal cost (min) was based on the lowest recommended parenteral daily dose and the maximal cost (max) was based on the highest recommended parenteral daily dose.</p></sec></sec><sec><title>Results</title><p>Between January 1, 2000, and June 30, 2003, a total of 8460 patients were admitted to the adult ICUs. Overall, 817 patients developed 1407 episodes of nosocomial infections, accounting for an infection rate of 16,6%. Among them, 233 patients (mean age:50,1; sex ratio female:male 0,49) had only one nosocomial infection. Mean daily antibiotic cost was found $89,64 per infected patient ($8,56 to $359,28).</p><p>Among the sites of nosocomial infections, urinary tract infections had the lowest daily antibiotic cost per infected patient (Table <xref ref-type="table" rid="T1">1</xref>). The mean daily antibiotic cost for pneumonia was the highest of all sites, but patients with bloodstream infection reached the highest range of daily cost ($31,31 to $359,28). In addition, mean daily antibiotic cost was found $162,35 for seventeen other infections including postoperative meningitis, mediastinitis, and empyema.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Daily antibiotic costs according to the sites of nosocomial infections.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Site of nosocomial infections</td><td align="center">Number of patients</td><td align="center">Range of daily cost per infected (US$)</td><td align="center">Mean (US$)</td></tr></thead><tbody><tr><td align="left">Pneumonia</td><td align="center">111</td><td align="center">10,02&#x02013;250,74</td><td align="center">99,02</td></tr><tr><td align="left">Bloodstream infections</td><td align="center">28</td><td align="center">31,31&#x02013;359,28</td><td align="center">94,32</td></tr><tr><td align="left">Surgical site infections</td><td align="center">11</td><td align="center">17,12&#x02013;204,74</td><td align="center">94,31</td></tr><tr><td align="left">Urinary tract infections</td><td align="center">66</td><td align="center">8,56&#x02013;228,68</td><td align="center">52,37</td></tr></tbody></table></table-wrap><p>Out of 233 patients, 206 patients had microbiologically documented infections, 177 patients were infected by a single pathogen while 29 patients were diagnosed as having polymicrobial infections (Table <xref ref-type="table" rid="T2">2</xref>). <italic>Pseudomonas aeruginosa </italic>was the most prevalent bacteria followed by <italic>Klebsiella </italic>spp. and <italic>Acinetobacter </italic>spp.. <italic>P. aeruginosa </italic>infections had the highest overall daily antibiotic cost per infected patient than other pathogens. Among 21 <italic>Staphylococcus aureus </italic>strains 15 (72%) were resistant to methicillin. The overall daily antibiotic cost of methicillin resistant <italic>S. aureus </italic>(MRSA) infections was two to three times higher than infections with susceptible strains. However, median daily cost per infected patient for MRSA infections were lower than susceptible strain infections.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Daily antibiotic cost according to the pathogens.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Pathogens</td><td align="center">No.</td><td align="center">Overall daily cost (US$)</td><td align="center">Range of daily cost per pathogen (US$)</td><td align="center">Median (US$)</td></tr></thead><tbody><tr><td align="left"><italic>Pseudomonas aeruginosa</italic></td><td align="center">60</td><td align="center">5567,06</td><td align="center">17,98&#x02013;204,74</td><td align="center">100,04</td></tr><tr><td align="left"><italic>Acinetobacter </italic>spp</td><td align="center">36</td><td align="center">4951,06</td><td align="center">17,98&#x02013;359,28</td><td align="center">92,47</td></tr><tr><td align="left"><italic>Stenotrophomonas maltophilia</italic></td><td align="center">4</td><td align="center">310,99</td><td align="center">31,31&#x02013;100,04</td><td align="center">89,82</td></tr><tr><td align="left"><italic>Klebsiella </italic>spp</td><td align="center">37</td><td align="center">3104,22</td><td align="center">10,02&#x02013;179,64</td><td align="center">79,6</td></tr><tr><td align="left"><italic>Enterobacter </italic>spp</td><td align="center">10</td><td align="center">961,79</td><td align="center">60,42&#x02013;139,08</td><td align="center">77,28</td></tr><tr><td align="left"><italic>Escherichia coli</italic></td><td align="center">23</td><td align="center">1652,57</td><td align="center">10,02&#x02013;179,64</td><td align="center">60,41</td></tr><tr><td align="left"><italic>Proteus </italic>spp</td><td align="center">3</td><td align="center">49,04</td><td align="center">13,24&#x02013;49,04</td><td align="center">49,04</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left" colspan="5"><italic>Staphylococcus aureus</italic></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">Methicillin-susceptible (MS)</td><td align="center">6</td><td align="center">476,22</td><td align="center">10,02&#x02013;142,2</td><td align="center">74,52</td></tr><tr><td align="left">Methicillin-resistance (MR)</td><td align="center">15</td><td align="center">1188,1</td><td align="center">35,88&#x02013;142,2</td><td align="center">71,1</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left" colspan="5">CoNS*</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">MS-CoNS</td><td align="center">1</td><td align="center">49,64</td><td align="center">16,34&#x02013;49,64</td><td align="center">49,64</td></tr><tr><td align="left">MR-CoNS</td><td align="center">3</td><td align="center">148,92</td><td align="center">17,52&#x02013;49,64</td><td align="center">49,64</td></tr><tr><td align="left"><italic>Enterococcus </italic>spp</td><td align="center">16</td><td align="center">1141,25</td><td align="center">32,29&#x02013;142,2</td><td align="center">49,64</td></tr><tr><td align="left"><italic>Candida </italic>spp</td><td align="center">21</td><td align="center">235,52</td><td align="center">8,56&#x02013;38,64</td><td align="center">8,56</td></tr><tr><td align="left">No pathogen identified</td><td align="center">27</td><td align="center">3166,75</td><td align="center">10,02&#x02013;359,28</td><td align="center">114,6</td></tr></tbody></table><table-wrap-foot><p>* Coagulase negative <italic>Staphylococcus</italic></p></table-wrap-foot></table-wrap><p>Among the 350 antibiotic prescriptions for nosocomial infections, piperacillin-tazobactam and amikacin were the most prescribed antibiotics (Table <xref ref-type="table" rid="T3">3</xref>). Carbapenems especially meropenem were the most expensive drugs.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Daily cost of antimicrobial agents for nosocomial infections.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Antimicrobial agents</td><td align="center">Number of prescriptions</td><td align="center" colspan="2">Daily cost per infected (US$)</td></tr><tr><td></td><td></td><td colspan="2"><hr></hr></td></tr><tr><td></td><td></td><td align="center">Min</td><td align="center">Max</td></tr></thead><tbody><tr><td align="left" colspan="4">Betalactams</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Ampicillin-sulbactam</td><td align="center">20</td><td align="center">23,92</td><td align="center">71,76</td></tr><tr><td align="left">Piperacillin-tazobactam</td><td align="center">48</td><td align="center">85,95</td><td align="center">114,6</td></tr><tr><td align="left">Ticarcillin-clavulanate</td><td align="center">4</td><td align="center">14,9</td><td align="center">22,35</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left" colspan="4">Carbapenems</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">&#x02003;Imipenem</td><td align="center">31</td><td align="center">100,04</td><td align="center">150,06</td></tr><tr><td align="left">&#x02003;Meropenem</td><td align="center">23</td><td align="center">179,64</td><td align="center">359,28</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left" colspan="4">Cephalosporins</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">&#x02003;Cefepime</td><td align="center">26</td><td align="center">38,64</td><td align="center">77,28</td></tr><tr><td align="left">&#x02003;Ceftazidime</td><td align="center">18</td><td align="center">35,82</td><td align="center">71,64</td></tr><tr><td align="left">&#x02003;Cefoperazone-sulbactam</td><td align="center">16</td><td align="center">40,28</td><td align="center">80,56</td></tr><tr><td align="left">&#x02003;Cefazoline</td><td align="center">10</td><td align="center">10,02</td><td align="center">20,04</td></tr><tr><td align="left">&#x02003;Ceftriaxone</td><td align="center">3</td><td align="center">19,7</td><td align="center">39,4</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left" colspan="4">Aminoglycosides*</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">&#x02003;Amikacin</td><td align="center">52</td><td align="center">-</td><td align="center">7,96</td></tr><tr><td align="left">&#x02003;Netilmicin</td><td align="center">21</td><td align="center">-</td><td align="center">24,48</td></tr><tr><td align="left">&#x02003;Tobramycin</td><td align="center">3</td><td align="center">-</td><td align="center">18,56</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left" colspan="4">Fluoroquinolones</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">&#x02003;Ciprofloxacin</td><td align="center">18</td><td align="center">49,04</td><td align="center">98,08</td></tr><tr><td align="left">&#x02003;Ofloxacin</td><td align="center">2</td><td align="center">25,74</td><td align="center">51,48</td></tr><tr><td align="left">&#x02003;Levofloxacin</td><td align="center">1</td><td align="center">41,07</td><td align="center">82,14</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left" colspan="4">Glycopeptides</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">&#x02003;Vancomycin</td><td align="center">13</td><td align="center">49,64</td><td align="center">87,27</td></tr><tr><td align="left">&#x02003;Teicoplanin</td><td align="center">12</td><td align="center">71,1</td><td align="center">142,2</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left" colspan="4">Other antibiotics</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">&#x02003;Clarithromycin</td><td align="center">4</td><td align="center">11,57</td><td align="center">23,14</td></tr><tr><td align="left">&#x02003;Trimethoprim-sulphamethoxazole</td><td align="center">2</td><td align="center">4,48</td><td align="center">8,96</td></tr><tr><td align="left">&#x02003;Metronidazole</td><td align="center">2</td><td align="center">5,51</td><td align="center">10,04</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left" colspan="4">Antifungal agents</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">&#x02003;Fluconazole</td><td align="center">21</td><td align="center">8,56</td><td align="center">34,24</td></tr><tr><td align="left">Total</td><td align="center">350</td><td align="center">8,56</td><td align="center">359,28</td></tr></tbody></table><table-wrap-foot><p>* dosage given as once-daily.</p></table-wrap-foot></table-wrap></sec><sec><title>Disscussion</title><p>Cost is an important factor which determines the physician's choice of medication to treat patients in spesific stiuations. In this study, we tried to demonstrate the daily cost of antimicrobial treatment of nosocomial infections according to site of infection, pathogen and antimicrobial agent.</p><p>In different studies, economical analysis regarding costs attributable to nosocomial infections has been evaluated and reported between $1018 to 2280 per infected patient [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. Jarvis et al reported that the estimated average costs of nosocomial infections were $558 to 593 for each urinary tract infection, $2734 for each surgical site infection, $3061 to 40000 for each bloodstream infection, and $4947 for each pneumonia [<xref ref-type="bibr" rid="B1">1</xref>].</p><p>Daily cost of antimicrobial treatment has been reported to be a significant extra cost attributable to nosocomial infections. In this study, we found an average daily antibiotic cost of $89,64 per nosocomial infection. It is clear that cost of overall antibiotic treatment for a period of approximately 10&#x02013;15 days is $900 to $1350. Prolongation of hospital stay has been the major extra cost attributable to nosocomial infections in many reports [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>], but in comparative case-control study from our country, Yalcin et al. [<xref ref-type="bibr" rid="B8">8</xref>] found that cost of antibiotic therapy of $1190 per infected patient, accounted for about 75% of the total extra cost. This finding may be due to the high prices of antibiotics in Turkey. To calculate the true costs of antibiotic therapy, hidden costs arising from intravenous administration, labor, serum antibiotic assay, monitoring hematological and biochemical indices and adverse effects of antibiotics must be considered [<xref ref-type="bibr" rid="B10">10</xref>]. The present study does not include these relevant "hidden costs" that could substantially modify the total cost of an antibiotic treatment. Although, hidden costs were not calculated, an average daily antibiotic cost of a single nosocomial infection is found to be markedly high in our hospital.</p><p>This result is within the limits reported by other large economic studies, suggesting that our data is comparable to those found in other countries and with other assessment methods. In a French prevalence survey, Astagneau et al.[<xref ref-type="bibr" rid="B11">11</xref>] reported an average daily antibiotic cost between FF 520 to 1085 (about $86 to $160) per nosocomial infection. French et al.[<xref ref-type="bibr" rid="B12">12</xref>] and Haley et al.[<xref ref-type="bibr" rid="B13">13</xref>] reported an average cost of antibiotic treatment of $190 and between $72 to $128 per nosocomial infection, respectively. In Turkey, Yalcin et al.[<xref ref-type="bibr" rid="B14">14</xref>] found that daily antibiotic cost of nosocomial infections was $70 per patient.</p><p>The daily antibiotic cost varies markedly according to site of infection. Our study has demonstrated that pneumonia and bloodstream infections were associated with the highest daily antibiotic costs as reported in other studies [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. Surgical site infections had also high daily antibiotic cost in our study. In their case-control study, Coello et al. reported that antibiotic therapy for surgical patients was the second most significant contributor to cost [<xref ref-type="bibr" rid="B15">15</xref>]. In the present study, nosocomially infected patients that had only one nosocomial infection were considered for analysis. Clearly, antimicrobial treatment of patients with multiple nosocomial infections might be much more expensive.</p><p><italic>P. aeruginosa </italic>infections had the highest daily antibiotic cost followed by other non-fermentative bacilli. Infections caused by <italic>P. aeruginosa </italic>are difficult to treat because of its virulence and relatively limited choice of effective antimicrobial agents, so, these infections often require combination therapy. Emergence of resistance in <italic>P. aeruginosa </italic>has been associated with increased morbidity, mortality, and costs [<xref ref-type="bibr" rid="B16">16</xref>]. On the other hand, although the overall antibiotic cost of MRSA infections was higher than infections with susceptible strains, the daily antibiotic cost per infected patient with MRSA was lower with susceptible strain infections. MRSA infections are treated by glycopeptides which cost less than beta-lactams in our country. Astagneau et al reported that the daily antibiotic cost of multi-resistant bacterial infections such as multi-resistant <italic>P. aeruginosa </italic>infections, was 20% higher than susceptible infections, but the daily antibiotic cost per infected patient for MRSA infections was not higher than for susceptible strain infections [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>Expensive antibiotics, such as piperacillin-tazobactam, carbapenems, cefepime, ciprofloxacin, teicoplanin were prescribed more commonly than the cheaper agents such as ampicillin-sulbactam, ceftriaxone or ofloxacin in our ICUs. These expensive antibiotics were mainly prescribed for resistant and severe gram-negative nosocomial infections, such as ventilator-associated pneumonia and postneurosurgical meningitis in ICU. Physicians may be forced to choose empirical antibiotic therapy with broad spectrum antimicrobials by increasing bacterial multi-resistance.</p><p>In conclusion, mean daily antibiotic cost was found $89,64 per nosocomial infection in our ICUs and nosocomial pneumonia had the highest daily antibiotic cost per infected patient. It is clear that cost of antibiotic therapy of nosocomial infections is an important part of extra cost attributable to nosocomial infection. Approximately one third of nosocomial infections are preventable by full implementation of the current infection control guideline recommendations [<xref ref-type="bibr" rid="B17">17</xref>]. Each institution should develope empirical antibiotic guidelines according to its own local nosocomial infections data. Infection control measures, such as education of health care workers regarding antimicrobial agents and resistance; isolation of patients infected with multi-resistant organisms, should be implemented to reduce infections and expensive antibiotic prescriptions.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' conributions</title><p>DI collated and analyzed the data, participated in the study design and was principal writer of manuscript. ANY conceived the study. GO carried out the laboratory studies. RS, FG, OT and LM participated in the patient management. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/5/5/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgments</title><p>The authors thank Ms. Sevim Keskin, an infection control nurse, for her valuable collaboration. This study was supported by Akdeniz University Scientific Research Project Unit.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jarvis</surname><given-names>WR</given-names></name></person-group><article-title>Selected aspects of socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention</article-title><source>Infect Control Hosp Epidemiol</source><year>1996</year><volume>17</volume><fpage>552</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">8875302</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zoutman</surname><given-names>D</given-names></name><name><surname>McDonald</surname><given-names>S</given-names></name><name><surname>Vethanayagan</surname><given-names>D</given-names></name></person-group><article-title>Total and attributable costs of surgical-wound infections at a Canadian tertiary-care center</article-title><source>Infect Control Hosp Epidemiol</source><year>1998</year><volume>19</volume><fpage>254</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">9605274</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plowman</surname><given-names>R</given-names></name><name><surname>Graves</surname><given-names>N</given-names></name><name><surname>Griffin</surname><given-names>MAS</given-names></name><name><surname>Roberts</surname><given-names>JA</given-names></name><name><surname>Swan</surname><given-names>AV</given-names></name><name><surname>Cookson</surname><given-names>B</given-names></name><name><surname>Taylor</surname><given-names>L</given-names></name></person-group><article-title>The rate and cost of hospital acquired infections occurring in patients addmitted to selected specialties of a district general hospital in England and the national burden imposed</article-title><source>J Hosp Infect</source><year>2001</year><volume>47</volume><fpage>198</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">11247680</pub-id><pub-id pub-id-type="doi">10.1053/jhin.2000.0881</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahieu</surname><given-names>LM</given-names></name><name><surname>Buitenweg</surname><given-names>N</given-names></name><name><surname>Beutels</surname><given-names>P</given-names></name><name><surname>De Dooy</surname><given-names>JJ</given-names></name></person-group><article-title>Additional hospital stay and charges due to hospital-acquired infections in a neonatal intensive care unit</article-title><source>J Hosp Infect</source><year>2001</year><volume>47</volume><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">11247683</pub-id><pub-id pub-id-type="doi">10.1053/jhin.2000.0852</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garner</surname><given-names>JS</given-names></name><name><surname>Jarvis</surname><given-names>WR</given-names></name><name><surname>Emori</surname><given-names>TG</given-names></name><name><surname>Horan</surname><given-names>TC</given-names></name><name><surname>Hughes</surname><given-names>JM</given-names></name></person-group><article-title>CDC definitions for nosocomial infections</article-title><source>Am J Infect Control</source><year>1988</year><volume>16</volume><fpage>128</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">2841893</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horan</surname><given-names>TC</given-names></name><name><surname>Gaynes</surname><given-names>RP</given-names></name><name><surname>Martone</surname><given-names>WY</given-names></name><name><surname>Jarvis</surname><given-names>WR</given-names></name><name><surname>Emori</surname><given-names>TG</given-names></name></person-group><article-title>CDC definitions of nosocomial surgical site infections. 1992: A modification of CDC definitions of surgical wound infections</article-title><source>Infect Control Hosp Epidemiol</source><year>1992</year><volume>13</volume><fpage>606</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">1334988</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haley</surname><given-names>RW</given-names></name><name><surname>Schaberg</surname><given-names>DR</given-names></name><name><surname>Van Allmen</surname><given-names>SD</given-names></name><name><surname>Mc Gowen</surname><given-names>JE</given-names></name></person-group><article-title>Estimating the extra charges and prolongation of hospitalization due to nosocomial infections: a comparison of methods</article-title><source>J Infect Dis</source><year>1980</year><volume>141</volume><fpage>248</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">6767793</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yalcin</surname><given-names>AN</given-names></name><name><surname>Hayran</surname><given-names>M</given-names></name><name><surname>Unal</surname><given-names>S</given-names></name></person-group><article-title>Economic analysis of nosocomial infections in a Turkish University Hospital</article-title><source>J Chemother</source><year>1997</year><volume>9</volume><fpage>411</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">9491840</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>BM</given-names></name></person-group><article-title>Economic consequences of hospital infections in a 1000 bed university hospital in Norway</article-title><source>Infect Control Hosp Epidemiol</source><year>1998</year><volume>19</volume><fpage>805</fpage><lpage>807</lpage><pub-id pub-id-type="pmid">9801295</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>JR</given-names></name><name><surname>Borr</surname><given-names>JG</given-names></name><name><surname>Smyth</surname><given-names>ETM</given-names></name><name><surname>O'Hare</surname><given-names>J</given-names></name></person-group><article-title>Technique for calculation of the true costs of antibiotic therapy</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>1992</year><volume>11</volume><fpage>823</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">1468420</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Astagneau</surname><given-names>P</given-names></name><name><surname>Fleury</surname><given-names>L</given-names></name><name><surname>Leroy</surname><given-names>S</given-names></name><name><surname>Lucet</surname><given-names>JC</given-names></name><name><surname>Golliot</surname><given-names>F</given-names></name><name><surname>Regnier</surname><given-names>B</given-names></name><name><surname>Brucker</surname><given-names>G</given-names></name></person-group><article-title>Cost of antimicrobial treatment for nosocomial infections based on a French prevalence survey</article-title><source>J Hosp Infect</source><year>1999</year><volume>42</volume><fpage>303</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">10467544</pub-id><pub-id pub-id-type="doi">10.1053/jhin.1998.0612</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>French</surname><given-names>GL</given-names></name><name><surname>Cheng</surname><given-names>AFB</given-names></name></person-group><article-title>Measurement of the costs of hospital infection by prevalence surveys</article-title><source>J Hosp Infect</source><year>1991</year><fpage>65S</fpage><lpage>72S</lpage><pub-id pub-id-type="doi">10.1016/0195-6701(91)90005-S</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haley</surname><given-names>RW</given-names></name></person-group><article-title>Measuring the costs of nosocomial infections: methods for estimating the economic burden on the hospital</article-title><source>Am J Med</source><year>1991</year><fpage>32S</fpage><lpage>38S</lpage><pub-id pub-id-type="pmid">1928186</pub-id><pub-id pub-id-type="doi">10.1016/0002-9343(91)90341-T</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yalcin</surname><given-names>AN</given-names></name><name><surname>Turgut</surname><given-names>H</given-names></name><name><surname>Cetin</surname><given-names>CB</given-names></name><name><surname>Tefci</surname><given-names>F</given-names></name></person-group><article-title>Cost of antimicrobial therapy in nosocomial infections [In Turkish ]</article-title><source>Turkish Journal of Hospital Infection</source><year>2002</year><volume>6</volume><fpage>41</fpage><lpage>45</lpage></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coello</surname><given-names>R</given-names></name><name><surname>Glenister</surname><given-names>H</given-names></name><name><surname>Fereres</surname><given-names>J</given-names></name><name><surname>Bartlett</surname><given-names>C</given-names></name><name><surname>Leigh</surname><given-names>D</given-names></name><name><surname>Sedgwick</surname><given-names>J</given-names></name><name><surname>Cooke</surname><given-names>EM</given-names></name></person-group><article-title>The cost of infection in surgical patients: a case-control study</article-title><source>J Hosp Infect</source><year>1993</year><volume>25</volume><fpage>239</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">7907621</pub-id><pub-id pub-id-type="doi">10.1016/0195-6701(93)90110-L</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carmeli</surname><given-names>Y</given-names></name><name><surname>Troillet</surname><given-names>N</given-names></name><name><surname>Karchmer</surname><given-names>AW</given-names></name><name><surname>Samore</surname><given-names>MH</given-names></name></person-group><article-title><italic>Pseudomonas aeruginosa: </italic>health and economic impact of antibiotic resistance and emergence of resistance</article-title><source>Arch Intern Med</source><year>1999</year><volume>159</volume><fpage>1127</fpage><lpage>1132</lpage><pub-id pub-id-type="pmid">10335691</pub-id><pub-id pub-id-type="doi">10.1001/archinte.159.10.1127</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haley</surname><given-names>RW</given-names></name><name><surname>Culver</surname><given-names>DH</given-names></name><name><surname>White</surname><given-names>JW</given-names></name><name><surname>Morgan</surname><given-names>WM</given-names></name><name><surname>Emori</surname><given-names>TG</given-names></name><name><surname>Munn</surname><given-names>VP</given-names></name><name><surname>Hooton</surname><given-names>TM</given-names></name></person-group><article-title>The efficacy of infection surveillance and control programs in preventing nosocomial infections in US Hospitals</article-title><source>Am J Epidemiol</source><year>1985</year><volume>121</volume><fpage>182</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">4014115</pub-id></citation></ref></ref-list></back></article>



